

RESEARCH ARTICLE

Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers

CME

Pierre-Emmanuel Sugier, PhD,^{1,2*} Elise A. Lucotte, PhD,¹ Cloé Domenighetti, PhD,¹ Matthew H. Law, PhD,^{3,4} Mark M. Iles, PhD,⁵ Kevin Brown, PhD,⁶ Christopher Amos, PhD,⁷ James D. McKay, PhD,⁸ Rayjean J. Hung, PhD,^{9,10} Mojgan Karimi, MSc,¹ Delphine Bacq-Daian, MSc,¹¹ Anne Boland-Augé, PhD,¹¹ Robert Olasso, PhD,¹¹ Jean-françois Deleuze, PhD,¹¹ Fabienne Lesueur, PhD,¹² Evgenia Ostroumova, PhD,⁸ Ausrele Kesminiene, MD,⁸ Florent de Vathaire, PhD,¹³ Pascal Guénel, MD, PhD,¹ on behalf of the EPITHYR consortium, Ashwin Ashok Kumar Sreelatha, PhD,¹⁴ Claudia Schulte, MSc,^{15,16} Sandeep Grover, PhD,¹⁴ Patrick May, PhD,¹⁷ Dheeraj R. Bobbili, PhD,¹⁷ Milena Radivojkovic-Blagojevic, MSc,¹⁸ Peter Lichtner, PhD,¹⁸ Andrew B. Singleton, PhD,^{19,20} Dena G. Hernandez, PhD,¹⁹ Connor Edsall, PhD,¹⁹ George D. Mellick, PhD,²¹ Alexander Zimprich, MD,²² Walter Pirker, MD,²³ Ekaterina Rogaeva, PhD,²⁴ Anthony E. Lang, MD,^{25,26,27} Sulev Koks, MD, PhD,^{28,29} Pille Taba, MD, PhD, FEAN,^{30,31} Suzanne Lesage, PhD,³² Alexis Brice, MD,³² Jean-Christophe Corvol, MD, PhD,^{32,33} Marie-Christine Chartier-Harlin, PhD,³⁴ Eugénie Mutez, MD,³⁴ Kathrin Brockmann, MD,^{15,16} Angela B. Deutschländer, MD,^{35,36} Georges M. Hadjigeorgiou, MD,^{37,38,39} Efthimios Dardiotis, MD,³⁸ Leonidas Stefanis, MD, PhD,^{40,41} Athina Maria Simitsi, MD, PhD,⁴⁰ Enza Maria Valente, MD, PhD,^{42,43} Simona Petrucci, MD, PhD,^{44,45} Letizia Straniero, PhD,⁴⁶ Anna Zecchinelli, MD,⁴⁷ Gianni Pezzoli, MD,⁴⁸ Laura Brighina, MD, PhD,^{49,50} Carlo Ferrarese, MD, PhD,^{49,50} Grazia Annesi, PhD,⁵¹ Andrea Quattrone, MD,^{52,53} Monica Gagliardi, PhD,⁵³ Hirotaka Matsuo, MD, PhD,⁵⁴ Akiyoshi Nakayama, MD,⁵⁴ Nobutaka Hattori, MD, PhD,⁵⁵ Kenya Nishioka, MD, PhD,⁵⁵ Sun Ju Chung, MD, PhD,⁵⁶ Yun Joong Kim, MD, PhD,⁵⁷ Pierre Kolber, MD,⁵⁸ Bart P.C. van de Warrenburg, MD, PhD,⁵⁹ Bastiaan R. Bloem, MD, PhD,⁵⁹ Jan Aasly, MD,⁶⁰ Mathias Toft, MD, PhD,⁶¹ Lasse Pihlström, MD, PhD,⁶¹ Leonor Correia Guedes, MD, PhD,^{62,63} Joaquim J. Ferreira, MD, PhD,^{62,63,64} Soraya Bardién, PhD,⁶⁵ Jonathan Carr, PhD,⁶⁶ Eduardo Tolosa, MD, PhD,^{67,68} Mario Ezquerra, PhD,⁶⁹ Pau Pastor, MD, PhD,⁷⁰ Monica Diez-Fairen, MSc,^{71,72} Karin Wirdefeldt, MD, PhD,^{73,74} Nancy Pedersen, PhD,⁷⁴ Caroline Ran, PhD,⁷⁵ Andrea C. Belin, PhD,⁷⁵ Andreas Puschmann, MD, PhD,⁷⁶ Emil Ygland Rödström, MD, PhD,⁷⁶ Carl E. Clarke, MD,⁷⁷ Karen E. Morrison, MD,⁷⁸ Manuela Tan, PhD,⁶¹ Dimitri Krainc, MD, PhD,⁷⁹ Lena F. Burbulla, PhD,^{16,79,80,81} Matt J. Farrer, PhD,⁸² Rejko Kruger, MD,^{17,83,84,85} Thomas Gasser, MD,^{15,16} Manu Sharma, PhD,^{14,15} on behalf of the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (Courage-PD) consortium, Thérèse Truong, PhD,¹ and Alexis Elbaz, MD, PhD,¹

¹ Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Team "Exposome, Heredity, Cancer and Health", CESP, Villejuif, France

² Laboratoire de Mathématiques et de leurs Applications de Pau, E2S UPPA, CNRS, Pau, France

³ Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia

⁴ Faculty of Health, Queensland University of Technology, Brisbane, Australia

⁵ Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

⁶ Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

⁷ Institute for Clinical and Translational Research, Baylor Medical College of Medicine, Houston, Texas, USA

⁸ International Agency for Research on Cancer, Lyon, France

⁹ Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada

¹⁰ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

This is an open access article under the terms of the [Creative Commons Attribution](#) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

***Correspondence to:** Dr. Pierre-Emmanuel Sugier, INSERM U1018 CESP, Hôpital Paul Brousse, Bâtiment 15/16, 16 avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France; E-mail: pe.sugier@univ-pau.fr

Thérèse Truong and Alexis Elbaz contributed equally to this work.

Additional Courage-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease), International Lung Cancer Consortium (ILCCO), and MMAC investigators are listed in the Appendix.

Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.

Relevant conflicts of interest/financial disclosures: Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 26 September 2022; **Revised:** 7 December 2022; **Accepted:** 28 December 2022

Published online 14 February 2023 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29337

- ¹¹Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, Evry, France
- ¹²Inserm, U900, Institut Curie, PSL University, Mines ParisTech, Paris, France
- ¹³Université Paris-Saclay, UVSQ, Gustave Roussy, Inserm, Team "Epidemiology of radiations," CESP, Villejuif, France
- ¹⁴Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany
- ¹⁵Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- ¹⁶German Center for Neurodegenerative Diseases, Tübingen, Germany
- ¹⁷Translational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg
- ¹⁸Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany
- ¹⁹Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA
- ²⁰Center For Alzheimer's and Related Dementias, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA
- ²¹Griffith Institute for Drug Discovery, Griffith University, Nathan, Australia
- ²²Department of Neurology, Medical University of Vienna, Vienna, Austria
- ²³Department of Neurology, Klinik Ottakring, Vienna, Austria
- ²⁴Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada
- ²⁵Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
- ²⁶Division of Neurology, University of Toronto, Toronto, Ontario, Canada
- ²⁷Krembil Brain Institute, Toronto, Ontario, Canada
- ²⁸Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia
- ²⁹Perron Institute for Neurological and Translational Science, Nedlands, Australia
- ³⁰Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
- ³¹Neurology Clinic, Tartu University Hospital, Tartu, Estonia
- ³²Department of Neurology, Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Paris, France
- ³³Assistance Publique Hôpitaux de Paris, Department of Neurology, CIC Neurosciences, Paris, France
- ³⁴Université de Lille, Inserm, CHU Lille, UMR-S 1172, LiNCog, Centre de Recherche Lille Neurosciences & Cognition, Lille, France
- ³⁵Department of Neurology, Ludwig Maximilians University of Munich, Munich, Germany
- ³⁶Department of Neurology, Max Planck Institute of Psychiatry, Munich, Germany
- ³⁷Department of Neurology and Department of Clinical Genomics, Mayo Clinic Florida, Jacksonville, Florida, USA
- ³⁸Department of Neurology, Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Larissa, Greece
- ³⁹Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus
- ⁴⁰1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- ⁴¹Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
- ⁴²Department of Molecular Medicine, University of Pavia, Pavia, Italy
- ⁴³Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation, Pavia, Italy
- ⁴⁴UOC Medical Genetics and Advanced Cell Diagnostics, S. Andrea University Hospital, Rome, Italy
- ⁴⁵Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy
- ⁴⁶Department of Biomedical Sciences, Humanitas University, Milan, Italy
- ⁴⁷Parkinson Institute, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milan, Italy
- ⁴⁸Parkinson Institute, Fontazione Grigioni-Via Zuretti, Milan, Italy
- ⁴⁹Department of Neurology, San Gerardo Hospital, Monza, Italy
- ⁵⁰Department of Medicine and Surgery and Milan Center for Neuroscience, University of Milano Bicocca, Milan, Italy
- ⁵¹Institute for Biomedical Research and Innovation, National Research Council, Cosenza, Italy
- ⁵²Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy
- ⁵³Department of Medical and Surgical Sciences, Neuroscience Research Center, Magna Graecia University, Catanzaro, Italy
- ⁵⁴Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Saitama, Japan
- ⁵⁵Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
- ⁵⁶Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- ⁵⁷Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea
- ⁵⁸Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
- ⁵⁹Department of Neurology, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands
- ⁶⁰Department of Neurology, St. Olav's Hospital and Norwegian University of Science and Technology, Trondheim, Norway
- ⁶¹Department of Neurology, Oslo University Hospital, Oslo, Norway
- ⁶²Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- ⁶³Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal
- ⁶⁴Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- ⁶⁵Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
- ⁶⁶Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa
- ⁶⁷Parkinson's Disease & Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

- ⁶⁸Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain
- ⁶⁹Lab of Parkinson's disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain
- ⁷⁰Unit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Barcelona, Spain
- ⁷¹Fundació per la Recerca Biomèdica i Social Mútua Terrassa, Barcelona, Spain
- ⁷²Movement Disorders Unit, Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain
- ⁷³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- ⁷⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- ⁷⁵Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
- ⁷⁶Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden
- ⁷⁷University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
- ⁷⁸Faculty of Medicine, Health and Life Sciences, Queens University, Belfast, United Kingdom
- ⁷⁹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- ⁸⁰Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
- ⁸¹Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- ⁸²Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
- ⁸³Neurology, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
- ⁸⁴Parkinson's Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
- ⁸⁵Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg

ABSTRACT: Background: Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties.

Objective: We used results from genome-wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors.

Methods: We used individual data for participants of European ancestry from the Courage-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta-Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa,

using cross-phenotypes polygenic risk score (PRS) analyses.

Results: We confirmed a previously reported positive genetic correlation of PD with melanoma ($G_{\text{corr}} = 0.16$ [0.04; 0.28]) and reported an additional significant positive correlation of PD with prostate cancer ($G_{\text{corr}} = 0.11$ [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the *NSF* gene (17q21.31).

Conclusions: We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Key Words: Parkinson's disease; cancer; genetic correlation; polygenic risk score; pleiotropy

Introduction

Although the frequency of cancers and neurodegenerative diseases increases with age, their cellular consequences are very different, with cell proliferation in cancers and neuronal death in neurodegenerative diseases. Parkinson's disease (PD) is caused by the loss

of dopaminergic neurons in the substantia nigra pars compacta.

Epidemiological studies that examined the association between PD and cancer support a general inverse association, ie, patients with PD tend to have a lower risk for cancer in general and cancer patients have a lower risk for PD.¹ This inverse association is mostly

explained by an inverse association with smoking-related cancers (lung, bladder, and colorectal cancers) because of a lower prevalence of smoking in patients with PD, but an inverse association has also been reported for some non-smoking-related cancers.^{1,2} In addition, after stratification on smoking status, two studies found an inverse association between smoking-related cancers and PD among ever smokers, whereas there was a positive association among never smokers,^{3,4} in favor of an interaction with smoking. In addition to smoking, other exposures associated with PD and cancer risk (eg, physical activity, reproductive factors in women) may also contribute to confound PD–cancer associations. Other possible biases in epidemiological studies include diagnostic bias, competing risks, or selective survival.^{5–7}

Alternatively, positive associations between PD and specific cancers (melanoma, skin, breast, brain, and prostate) have also been reported.^{1,8} In particular, the positive association between PD and melanoma is well established.⁹ This association exists both for melanomas occurring before and after PD diagnosis, which does not support the role of antiparkinsonian medications as a causal factor.¹⁰ It has been hypothesized that this association could be explained by common genetic factors, because people with a familial history of melanoma had an increased risk for PD and, conversely, relatives of patients with PD had an increased risk for melanoma.¹

Specific genes involved in familial forms of PD (*SNCA*, *Parkin*, *LRRK2*) have been implicated in biological mechanisms associated with breast, prostate, and thyroid cancers.^{1,11,12} Inactivation of *PARK2*, a gene that causes recessive forms of PD, is associated with an increased cancer risk, highlighting its role as tumor suppressor,¹³ particularly in breast and ovarian cancers.¹⁴ Epidemiological studies support an increased risk for cancer in *LRRK2*-G2019S carriers.¹⁵ There is also an overrepresentation of somatic mutations of *PARK* genes in melanoma cases.¹⁶ *PARK6* (*PINK1*) is also known to play a role in breast and ovarian cancers.¹⁷

A two-sample Mendelian randomization analysis did not find evidence in favor of a causal relationship between several cancers (including melanoma, breast, and prostate) and PD, thus suggesting that the previously reported associations between PD and cancers may be explained by pleiotropic genetic factors or shared biology.¹⁸ A study using a candidate gene approach found no association between PD (Population Architecture through Genomics and Environment [PAGE] study, International Parkinson Disease Genomics Consortium [iPDGC]) and genetic polymorphisms associated with melanoma or skin pigmentation in genome-wide association studies (GWASs).¹⁹ One study used iPDGC and 23andMe to show a positive significant genetic correlation between melanoma and PD.²⁰ Another study examined the genetic correlation between three neurodegenerative diseases and multiple cancers; for PD, they also used iPDGC and 23andMe data and showed positive

correlations with melanoma and prostate cancers, although these associations would not have been statistically significant after correction for multiple testing.²¹

In this article, we aimed at identifying common genetic risk factors of PD and cancers previously associated with PD (melanoma, breast, prostate) or for which an association is suspected (lung, ovary, thyroid). First, we estimated genetic correlations between PD and cancers using results from large GWASs and linkage disequilibrium (LD) score regression. Second, we analyzed the association of polygenic risk scores (PRSs) for PD (and their individual single-nucleotide polymorphisms [SNPs]) with each cancer and, conversely, the association of PRSs for each cancer (and their individual SNPs) with PD.

Subjects and Methods

GWAS Datasets on PD

We used data from two PD consortia: individual data from the Courage-PD consortium (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease)²² and summary statistics from iPDGC.^{23,24}

In Courage-PD, we excluded studies performed in Asian populations, studies that included cases only, and those with less than 50 cases and 50 controls. Only individuals from European ancestry were retained for the analysis. We also excluded individuals overlapping with iPDGC. We finally used data from 23 of 35 case–control studies, totaling 8919 cases and 7600 controls (Table S1). The NeuroChip array was used to genotype all the samples (see Supporting Information Methods). Imputation of autosomal variants was performed separately in each study, based on 271,398 to 373,664 SNPs. The mean number of SNPs available in each study after imputation was 13,710,549. In each study, SNP frequencies were compared in cases versus controls under an additive model using logistic regression adjusted for sex and the first four principal components. We meta-analyzed the summary statistics from the 23 GWASs using an inverse-variance fixed-effects ($I^2 \leq 25\%$) or random-effects ($I^2 > 25\%$) model (see Supporting Information Methods).

As a replication dataset for PD, we used GWAS summary statistics from the iPDGC consortium (33,674 cases, 449,056 controls).²³ Sex-stratified summary statistics are also available for 13,020 male PD cases, 7936 paternal proxy cases, 89,660 male controls, 7947 female PD cases, 5473 maternal proxy cases, and 90,662 female controls.²⁴

GWAS Datasets on Cancer

We used summary statistics from European ancestry-based GWASs on cancer susceptibility: Breast Cancer Association Consortium (BCAC)²⁵ (122,977 breast

cancer cases, 105,974 controls), Melanoma Meta-Analysis Consortium (MMAC)²⁶ (12,814 melanoma cases, 23,203 controls), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)²⁷ (79,148 prostate cancer cases, 61,106 controls), International Lung Cancer Consortium (ILCCO)²⁸ (29,266 lung cancer cases, 56,450 controls), Ovarian Cancer Association Consortium (OCAC)²⁹ (25,509 ovarian cancer cases, 40,941 controls), and Epidemiology of Thyroid Cancer Consortium (EPITHYR)³⁰ (1554 differentiated thyroid cancer cases, 1973 controls).

LD Score Regression

To investigate the genetic correlation between PD and each cancer, we performed cross-trait LD score regression.³¹ We performed one analysis for each PD–cancer pair using summary statistics from the corresponding GWAS. Before running the analyses, we implemented the following filters³¹: SNPs with imputation scores INFO > 0.9; minor allele frequency (MAF) > 0.01; harmonized to HapMap3 SNPs with 1000 Genomes EUR MAF > 0.05; and removal of indels, structural variants, strand-ambiguous SNPs, and SNPs whose alleles did not match those in 1000 Genomes. This was performed by running the *munge-sumstats.pr* script included in *ldsc*. We ran *ldsc.py* from the *ldsc* package after excluding the *HLA* region. The final numbers of SNPs considered for each pairwise genetic correlation analysis are reported in Table S2.

Genetic correlations were estimated separately for Courage-PD and iPDGC and were then meta-analyzed using an inverse-variance weighting method. We used the false discovery rate (FDR) to take into account multiple testing.

Cross-Phenotype PRS Analysis

Cross-phenotype PRS analysis allows investigating whether an individual-level genome-wide genetic prediction of a disease has substantive power to predict another disease. For each PD–cancer pair, we examined the association of the PRS for one of the diseases with the other disease, and vice versa.

PRSs for each cancer were aligned in Courage-PD using independent genome-wide significant SNPs and corresponding weights for PRS previously published in the largest GWAS to date on this cancer.^{27,28,32–36} The lists of SNPs and corresponding weights used for cancer PRSs are described in Table S3A–F. The association between cancer PRSs and PD was examined in each of the 23 studies of Courage-PD using logistic regression adjusted for sex and four principal components. An inverse-variance weighted meta-analysis of regression coefficients was then performed. The extent of heterogeneity was estimated using the I^2 statistic.³⁷ A random-effects meta-analysis was performed if $I^2 > 25\%$, and a

fixed-effects model was used otherwise. The association between cancer PRSs and PD was calculated in iPDGC, for which individual data were not available, using the *grs.summary* function from the *gtx* R package³⁸ based on summary statistics.

Analyses of the PD PRS in cancer were based on both 88 SNPs identified by Nalls et al²³ and 44 SNPs identified by Chang et al³⁹ to compare the results. For non-retrieved SNPs, we searched for proxies at $r^2 > 0.8$ with the *proxysnp*s function based on the 1000 Genomes Project (<https://github.com/slowkow/proxysnp>). We did not use one palindromic SNP (rs1555399) with MAF > 0.45. For thyroid cancer, we used the same strategy as for cancer PRSs in Courage-PD because individual data were available. For all other cancers for which individual data were not available, we used the same strategy as for the analysis between cancer PRSs and PD using summary statistics from iPDGC. Results of associations with PRSs for cancers in Courage-PD and iPDGC were meta-analyzed using the inverse-variance weighting method as described earlier. We calculated an FDR to correct for multiple testing for each direction of the cross-phenotype PRS analysis.

Shared Risk Loci

For PD–cancer pairs for which we identified a significant cross-phenotype PRS association, we further explored associations at the level of individual SNPs from the PRSs, to identify pleiotropic risk loci that influence these associations. For each PD–cancer pair, we determined which SNPs played a role while correcting for multiple testing using the FDR.

Stratified Analyses

Information on sex was available in Courage-PD and the latest iPDGC GWAS.²⁴ We examined the association of cancer PRSs with PD in men and women to identify sex-specific associations.

In addition, the ILCCO consortium performed GWASs stratified by smoking status (ever/never) and histology (small cell carcinoma, squamous cell carcinoma, and adenocarcinoma). This allowed us to examine the association of PD PRSs with lung cancer risk according to histology and smoking status.

Results

LD Score Regression

The meta-analysis of genetic correlations identified two significant positive genetic correlations of PD with melanoma ($G_{\text{corr-meta}} = 0.16$, $P_{\text{meta}} = 0.02$, FDR = 0.047) and prostate cancer ($G_{\text{corr-meta}} = 0.11$, $P_{\text{meta}} = 0.01$, FDR = 0.047) that remained significant after correction for multiple testing (FDR < 0.05) (Table 1). There was no heterogeneity between the Courage-PD

TABLE 1 Genetic correlations between PD and cancers

Cancer	Courage-PD			iPDGC			Meta-analysis				
	G _{corr}	CI _{95%}	P	G _{corr}	CI _{95%}	P	G _{corr}	CI _{95%}	P _{meta}	P _{het}	FDR
Breast cancer	0.06	[-0.06; 0.18]	0.36	0.04	[-0.06; 0.14]	0.46	0.05	[-0.03; 0.13]	0.24	0.84	0.37
Ovarian cancer	0.04	[-0.20; 0.28]	0.74	-0.13	[-0.27; 0.01]	0.07	-0.09	[-0.21; 0.03]	0.17	0.23	0.33
Melanoma	0.18	[-0.02; 0.38]	0.09	0.14	[-0.02; 0.30]	0.08	0.16	[0.04; 0.28]	0.02	0.80	0.047
Thyroid cancer	0.28	[-0.05; 0.61]	0.10	-0.02	[-0.33; 0.29]	0.88	0.11	[-0.13; 0.35]	0.32	0.19	0.39
Prostate cancer	0.11	[-0.03; 0.25]	0.10	0.11	[-0.01; 0.23]	0.05	0.11	[0.03; 0.19]	0.01	0.98	0.047
Lung cancer	0.14	[-0.02; 0.30]	0.10	-0.05	[-0.02; 0.09]	0.40	0.02	[-0.08; 0.12]	0.72	0.07	0.72

Abbreviations: PD, Parkinson's disease; iPDGC, International Parkinson Disease Genomics Consortium; CI_{95%}, 95% confidence interval; G_{corr}, genetic correlation; P_{meta}, P value from the meta-analysis of both datasets; FDR, false discovery rate.

TABLE 2 Association between cancer PRSs and PD

PRS	Courage-PD		iPDGC		Meta-analysis			
	OR [CI _{95%}]	P	OR [CI _{95%}]	P	OR [CI _{95%}]	P _{meta}	P _{het}	FDR
Breast cancer	1.05 [0.98; 1.12]	0.17	1.04 [0.99; 1.10]	0.15	1.04 [1.00; 1.09]	0.05	0.86	0.10
Ovarian cancer	0.88 [0.80; 0.96]	5.2×10^{-3}	0.90 [0.84; 0.96]	1.2×10^{-3}	0.89 [0.84; 0.94]	2.1×10^{-5}	0.76	1.1×10^{-4}
Melanoma	0.99 [0.86; 1.15]	0.90	1.09 [0.98; 1.22]	0.11	1.06 [0.97; 1.15]	0.22	0.29	0.33
Thyroid cancer	1.02 [0.96; 1.08]	0.53	1.00 [0.96; 1.05]	0.96	1.01 [0.97; 1.04]	0.65	0.66	0.65
Prostate cancer	1.01 [0.96; 1.07]	0.61	1.01 [0.97; 1.06]	0.57	1.01 [0.98; 1.05]	0.44	0.96	0.53
Lung cancer	1.00 [0.92; 1.09]	0.94	1.10 [1.03; 1.17]	5.5×10^{-3}	1.06 [1.01; 1.12]	0.02	0.11	0.07

Abbreviations: PRS, polygenic risk score; PD, Parkinson's disease; iPDGC, International Parkinson Disease Genomics Consortium; OR, odds ratio; CI_{95%}, 95% confidence interval; P_{meta}, P value from the meta-analysis of both datasets; P_{het}, P value of heterogeneity; FDR, false discovery rate.

and iPDGC datasets. The genetic correlation between PD and breast cancer was positive and consistent in both datasets, but not statistically significant ($P_{\text{meta}} = 0.24$, FDR = 0.37). The other three cancers showed heterogeneous genetic correlations in sizes and directions between Courage-PD and iPDGC.

Cross-Phenotype PRS Analysis

Analyses of the association between cancer PRSs and PD are shown in Table 2. We found one significant inverse association between the PRS for ovarian cancer and PD ($P_{\text{meta}} = 2.1 \times 10^{-5}$, FDR = 1.1×10^{-4}). Suggestive positive associations were observed for the PRS for breast cancer ($P_{\text{meta}} = 0.05$, FDR = 0.10) and lung cancer ($P_{\text{meta}} = 0.02$, FDR = 0.07) with PD, but these associations became nonsignificant after correction for multiple testing.

Regarding the association between the PD PRSs and cancers (Table 3), we found a positive association between both PD PRSs and breast cancer, with a stronger association for the PRS_{Chang} (odds ratio [OR]

= 1.08, $P = 4.6 \times 10^{-14}$, FDR = 2.7×10^{-13}) than PRS_{Nalls} (OR = 1.03, $P = 1.9 \times 10^{-4}$, FDR = 1.14×10^{-3}). We also found an inverse association between the PRS_{Chang} and ovarian cancer (OR = 0.95, $P = 0.013$, FDR = 0.04); the association was similar for the PRS_{Nalls}, but it was borderline significant and became nonsignificant after correction for multiple testing.

Shared Risk Loci

We searched for pleiotropic SNPs between PD and breast cancer on one side, and between PD and ovarian cancer on the other side, by examining associations for individual SNPs included in the PD, breast cancer, or ovarian cancer PRSs (Tables S4A–D and S5A–D).

The PRSs for PD and ovarian cancer share a common region on locus 17q21.31 that was also associated with breast cancer (Tables 4 and 5). This region is represented by four SNPs in high LD: rs183211, rs17649553, rs62053943 (pairwise $r^2 > 0.7$, $D' = 1$ in 1000 Genome CEU), and rs117615688 ($r^2 < 0.14$, $D' = 1$ with the three other SNPs). Associations with these SNPs were

TABLE 3 Association between PD PRSs and cancers

Disease	PRS _{Chang}			PRS _{Nalls}		
	OR [CI _{95%}]	P	FDR	OR [CI _{95%}]	P	FDR
Breast cancer	1.08 [1.06; 1.10]	4.6×10^{-14}	2.7×10^{-13}	1.03 [1.01; 1.05]	1.9×10^{-4}	1.14×10^{-3}
Ovarian cancer	0.95 [0.91; 0.99]	0.013	0.04	0.97 [0.94; 1.00]	0.07	0.21
Melanoma	1.04 [0.98; 1.11]	0.19	0.38	1.05 [1.00; 1.10]	0.43	0.43
Thyroid cancer	0.92 [0.79; 1.07]	0.30	0.45	0.93 [0.82; 1.05]	0.25	0.375
Prostate cancer	1.00 [0.97; 1.02]	0.80	0.80	1.01 [0.99; 1.03]	0.41	0.43
Lung cancer	0.94 [0.79; 1.13]	0.51	0.61	0.98 [0.95; 1.00]	0.16	0.32

Abbreviations: PD, Parkinson's disease; PRS, polygenic risk score; OR, odds ratio; CI_{95%}, 95% confidence interval; FDR, false discovery rate.

TABLE 4 SNPs of PRSs for PD associated with breast or ovarian cancer

Locus	Gene	SNP	Position (kb)	EA	BA	Weight in PRSs for PD		Type	Cancer		
						OR _{Chang}	OR _{Nalls}		OR	CI _{95%}	P
2q11.2	MAP4K4	rs11683001	102,396	A	T	–	1.07	Breast	1.03	[1.01, 1.04]	1.6×10^{-4}
2q11.2	MAP4K4	rs34043159	102,413	C	T	1.07	–	Breast	1.02	[1.01, 1.04]	2.8×10^{-4}
6p21.32	/	rs9275326	32,666	C	T	1.17	–	Breast	1.03	[1.01, 1.05]	1.8×10^{-3}
16q12.1	CASC16	rs4784227	52,599	T	C	1.08	–	Breast	1.24	[1.22, 1.26]	6.8×10^{-201}
	CASC16	rs3104783	52,636	A	C	–	1.07	Breast	1.10	[1.09, 1.11]	1.6×10^{-52}
17q21.2	RETREG3	rs12951632	40,741	T	C	–	1.07	Breast	0.98	[0.96, 0.99]	5.1×10^{-4}
17q21.31	CRHR1	rs62053943	43,744	C	T	–	1.31	Ovarian	0.89	[0.85, 0.92]	5.0×10^{-9}
						–	1.31	Breast	1.06	[1.04, 1.08]	8.6×10^{-11}
	CRHR1	rs117615688	43,798	G	A	–	1.26	Ovarian	0.91	[0.86, 0.96]	7.0×10^{-4}
						–	1.26	Breast	1.04	[1.01, 1.07]	8.7×10^{-3}
	MAPT	rs17649553	43,994	C	T	1.28	–	Ovarian	0.89	[0.87, 0.92]	1.2×10^{-12}
						1.28	–	Breast	1.05	[1.03, 1.07]	1.5×10^{-10}
17q23.2	BRIP1	rs61169879	59,917	T	C	–	1.09	Breast	1.03	[1.02, 1.05]	3.9×10^{-3}

Abbreviations: SNP, single-nucleotide polymorphism; PRS, polygenic risk score; PD, Parkinson's disease; EA, effect allele; BA, baseline allele; OR, odds ratio; CI_{95%}, 95% confidence interval.

in the same direction for PD and breast cancer, but in the inverse direction with ovarian cancer. These SNPs are located in introns of three different genes: *NSF* (N-ethylmaleimide-sensitive factor, vesicle fusing ATPase), *MAPT* (microtubule-associated protein tau), and *CRHR1* (Corticotropin-Releasing Hormone Receptor 1). These results are in favor of a common haplotype associated with the three diseases. The inverse cross-phenotype association between PD and ovarian cancer was mostly driven by this locus. No other SNPs of the PD PRS were significantly associated with ovarian cancer (or conversely) after correcting for multiple testing.

Of the SNPs from the PD PRSs, six were significantly associated with breast cancer and were located at five different loci (Table 4): 2q11.2 (in an intron of

MAP4K4, mitogen-activated protein kinase 4), 6p21.32, 16q12.1 (intronic region of *CASC16*, cancer susceptibility 16), 17q23.2 (in an intron of *BRIP1*, BRCA1 interacting protein C-terminal helix 1) with SNPs associated in the same direction, and 17q21.2 with SNPs inversely associated (in an intron of *RETREG3*, reticulophagy regulator family member 3).

Of the SNPs from the breast cancer PRS, rs3566861 located at 16q12.1 was in common with the PRS_{Chang}. The two SNPs at locus 16q12.1 from the breast cancer PRS are in high LD ($r^2 = 0.87$, $D' = 0.97$) and were associated with PD in iPDGC (rs4784227: OR = 1.08, $P = 9.4 \times 10^{-5}$; rs3566861: OR = 1.08, $P = 1.5 \times 10^{-4}$) (Table 5).

TABLE 5 SNPs of PRSs for breast or ovarian cancer associated with PD

Locus	Gene	SNP	Position (kb)	EA	BA	Cancer		Courage-PD			iPDGC		
						Type	OR PRS	OR	CI _{95%}	P	OR	CI _{95%}	P
16q12.1	CASC16	rs35668161	52,538	A	C	Breast	1.12	1.09	[1.03, 1.15]	3.6×10^{-3}	1.08	[1.04, 1.12]	1.5×10^{-4}
	CASC16	rs4784227	52,599	T	C	Breast	1.11	1.07	[1.01, 1.14]	0.02	1.08	[1.04, 1.12]	9.4×10^{-5}
17q21.31	NSF	rs183211	44,788	A	G	Ovarian	1.25	0.78	[0.74, 0.83]	1.8×10^{-17}	0.81	[0.77, 0.84]	9.0×10^{-21}

Abbreviations: SNP, single-nucleotide polymorphism; PRS, polygenic risk score; PD, Parkinson's disease; iPDGC, International Parkinson Disease Genomics Consortium; EA, effect allele; BA, baseline allele; OR PRS, odds ratio of the PRS; OR, odds ratio; CI_{95%}, 95% confidence interval.

Stratified Analyses

Associations of the cancer PRSs with PD in men and women are shown in Table S6A,B. The inverse association between the ovarian cancer PRS and PD was present both in women ($P_{\text{meta}} = 3.23 \times 10^{-4}$) and in men ($P_{\text{meta}} = 1.38 \times 10^{-4}$) with the same effect size (OR = 0.88) and similar associations in Courage-PD and iPDGC. The association of the breast cancer PRS with PD was stronger in men (OR = 1.08, $P_{\text{meta}} = 3 \times 10^{-3}$), in whom it was driven by iPDGC, than in women (OR = 1.05, $P_{\text{meta}} = 0.07$). The association between the lung cancer PRS and PD was present only in women (OR = 1.08, $P = 0.04$).

Associations between the PD PRS with different histology types of lung cancer are presented in Table S7. An inverse association was found between the PRS_{Nalls} and squamous cell carcinoma (OR_{Nalls} = 0.94, $P_{\text{Nalls}} = 8.0 \times 10^{-3}$). The association with PRS_{Chang} was in the same direction, but not significant (OR_{Chang} = 0.98, $P_{\text{Chang}} = 0.42$). Stratified analyses by smoking status in lung cancer showed an inverse association in ever smokers (OR_{Chang} = 0.96, $P_{\text{PRS-Chang}} = 0.086$; OR_{Nalls} = 0.95, $P_{\text{PRS-Nalls}} = 9.6 \times 10^{-3}$), but not in never smokers (OR_{Chang} = 1.07, $P_{\text{PRS-Chang}} = 0.28$; OR_{Nalls} = 1.02, $P_{\text{PRS-Nalls}} = 0.73$) (see Table S8). However, the interactions between the PD PRSs and smoking status did not reach statistical significance ($P_{\text{PRS-Chang}} = 0.097$, $P_{\text{PRS-Nalls}} = 0.20$).

Discussion

In this article, we investigated whether pleiotropy plays a role in the association between PD and cancers using GWAS data from two PD and six cancer consortia. We found significant positive genetic correlations of PD with melanoma and prostate cancer. Cross-phenotype analyses showed that the PD PRS was associated with a higher risk for breast cancer and a lower risk for ovarian cancer. The ovarian cancer PRS was also associated with a lower risk for PD.

Our finding of a positive correlation of PD with melanoma and prostate cancer is consistent with epidemiological studies reporting positive associations of PD with melanoma,^{1,10} whereas different directions of associations have been reported between PD and prostate cancer.^{1,40} The genetic correlation we identified between PD and melanoma ($G_{\text{corr}} = 0.16$ [0.04; 0.28]) is consistent with a previous study that used iPDGC and 23andMe data³⁹ to show a significant correlation of a similar magnitude ($G_{\text{corr}} = 0.17$ [0.10; 0.24]).²⁰ Another study examined the genetic correlation between three neurodegenerative diseases and multiple cancers; analyses for PD were based on iPDGC and 23andMe data and showed a significant positive correlations with melanoma ($G_{\text{corr}} = 0.14$, $P = 0.044$) and

prostate cancer (iPDGC: $G_{\text{corr}} = 0.09$, $P = 0.032$; 23andMe: $G_{\text{corr}} = 0.16$, $P = 0.044$) that would not have survived multiple testing correction.²¹ The authors also investigated the genetic correlation of PD with breast, ovarian, lung, and thyroid cancers and found no associations. The main difference between these two studies and ours is that, in addition to iPDGC data (excluding 23andMe), we also used data from a completely independent GWAS from the Courage-PD consortium.

We did not find significant correlations between PD and other cancers. However, the lack of correlation may be because of the fact that LD score allows to highlight only an overall trend of correlation. If shared loci of two diseases are randomly associated in different directions, an overall correlation would be masked by positively and negatively correlated regions that cancel each other out.

We explored the cross-phenotype PRS association between PD and cancers using two PRSs for PD. This allowed us to compare the results from the PRS proposed by Nalls et al.²³ and the previous one proposed by Chang et al.³⁹ The PRS_{Nalls} is more recent and included a higher number of SNPs but was determined in a population composed partly of proxy cases that could have led to some dilution of associations because of a less precise characterization of the disease. Both PD PRSs were associated with a higher risk for breast cancer. The breast cancer PRS was also associated with a higher risk for PD, but the association was no longer significant after correction for multiple testing. In addition, cross-phenotype analyses showed that the PD-PRS_{Chang} was associated with a lower risk for ovarian cancer. Consistently, the ovarian cancer PRS was also associated with a lower risk for PD. Associations between both PD PRSs with each cancer were consistent, but the association with ovarian cancer reached significance only for the PRS_{Chang}. To our knowledge, no published study has previously performed analyses of the cross-phenotype associations between PD and cancer.

Analyses of the associations between SNPs of the PRSs highlighted in cross-phenotype analyses showed that the inverse association between PD and ovarian cancer was mostly driven by one SNP in the 17q21.31 region. Three SNPs in this region were positively associated with breast cancer; they were not in LD with *BRCA1*, which is also located in this region. The gene *MAPT* in this region, tagged by SNPs of the PD-PRS, was already known as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy and as a marker of paclitaxel sensitivity in breast cancer.¹ Also, the gene *NSF* of the ovarian cancer PRS has already been reported to be associated with PD through the same SNP: rs183211. This gene has also been recently reported as associated with cancer pleiotropy (breast,

cervix, lung, melanoma, testis) in a pan-cancer study.⁴¹ Four other regions from the PD PRS were associated with breast cancer in the same direction (2q11.2, 6p21.32, 16q12.1, 17q23.2) and one region in the opposite direction (17q21.2). The breast cancer PRS was not significantly associated with PD after correction for multiple testing, but the positive association was detected at a suggestive threshold. Sex-stratified analyses did not show major differences between men and women in the association of the PRS for both ovarian cancer and breast cancer with PD.

We detected another positive association between PD and the PRS for lung cancer that was significant in iPDGC, but not in Courage-PD; in sex-stratified analyses, this positive association was present in women only, whereas it tended to be inverse, although not significant, in men. We also found an inverse association between the PD PRS_{Nalls} and squamous carcinomas of the lung. Cross-phenotype analyses of lung cancer stratified by smoking status showed an inverse association in ever smokers, whereas the association was positive in never smokers. These findings are consistent with the facts that squamous carcinomas are known to be the lung cancer histological type with the strongest association with tobacco,^{28,42} and that smoking rates are lower in women. There was a trend toward a gene-environment interaction that was not statistically significant, possibly because of the small number of never smokers compared with the number of ever smokers and small effect sizes.

Cross-phenotype PRS analyses in other cancers did not show any association with PD. However, multiple pleiotropic SNPs with different directions of associations may lead to diluting an association with PRSs.

The main strength of our study is that we used the largest GWAS available at the present date for several cancers together with two independent large PD datasets to replicate our findings, while correcting for multiple testing. Our study also has limitations. The size of the GWAS datasets was different for different phenotypes, and for some of them, we did not have access to individual data but rather GWAS summary statistics. The panels of SNPs available in each GWAS were also different, which could affect the results, especially for genetic correlation analysis. Although the NeuroChip array has reduced coverage compared with some other arrays, the tagging variant backbone of about 306,670 SNPs has good genome-wide resolution and allows to perform genome-wide imputation; in addition, we retained for our analyses SNPs with good-quality imputation ($r^2 \geq 0.8$). Our analyses are restricted to participants of European descent, and additional studies are needed in other populations. Finally, except for the lung cancer GWAS that performed analyses stratified by smoking, analyses stratified by environmental factors were not available for other cancer GWASs.

Epidemiological studies have identified a complex association between PD and cancers, but the underlying mechanisms remain poorly understood. In addition, epidemiological studies on the relation between neurodegenerative diseases and cancer face a number of methodological difficulties and possible biases, including confounding, diagnostic bias, competing risks, or selective survival.⁵⁻⁷ Alternatively, as for Mendelian randomization, the genetic approach we used is not affected by confounding, reverse causation, or surveillance biases because genes are randomly assigned at birth and are not influenced by exposures. In addition, we used GWASs for PD and cancer studies that were independent and did not include overlapping participants; hence in the cancer GWAS, the diagnosis was independent of PD, and vice versa. Studies based on a genetic approach are complementary to epidemiological studies and may help understand whether genetic pleiotropy could account for some of the associations highlighted by epidemiological studies. Our results suggest the importance of shared genetic variants between PD and some cancers. These analyses may be followed by analyses of genome-wide pleiotropy at a SNP, gene, or pathway level to better understand the shared biologic mechanisms between PD and cancer. It would also be interesting to explore additional environmental factors that could interact with pleiotropic genes associated with both PD and cancer. Evidence of pleiotropy between PD and cancer will improve our understanding of the etiology of these diseases and will provide insights into their underlying biology. ■

Acknowledgments: We thank the Breast Cancer Association Consortium, the Ovarian Cancer Association Consortium, the PRACTICA Consortium, CRUK, BPC3, CAPS, PEGASUS for providing summary statistics from GWAS on cancers, and iPDGC for summary statistics from GWAS on PD.

Appendix

Additional Courage-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease) investigators: S.N. Pchelina (Saint Petersburg, Russia), T. Brücke (Wien, Austria), M.-A. Lorient (Paris, France), C. Mulot (Paris, France), Y. Koudou (Villejuif, France), A. Destée (Lille, France), G. Xiomerisiou (Larissa, Greece), C. Koros (Athens, Greece), M. Maniati (Athens, Greece), M. Bozi (Athens, Greece), M. Avenali (Pavia, Italy), S. Duga (Milan, Italy), M. Canesi (Milan, Italy), G. Sacilotto (Milan, Italy), M. Zini (Milan, Italy), R. Cilia (Milan, Italy), F. Del Sorbo (Milan, Italy), N. Meucci (Milan, Italy), R. Asselta (Milan, Italy), R. Procopio (Catanzaro, Italy), M. Funayama (Tokyo, Japan), A. Ikeda (Tokyo, Japan), T. Matsushima (Tokyo, Japan), Y. Li (Tokyo, Japan), H. Yoshino (Tokyo, Japan), Z. Landoulsi (Luxembourg,

Luxembourg), R. Fernández-Santiago (Barcelona, Spain), N. Wood (London, UK), and H.R. Morris (London, UK).

Additional ILCCO (International Lung Cancer Consortium) investigators: D. Albanes (Bethesda, MD, USA), M.T. Landi (Bethesda, MD, USA), S. Lam (Vancouver, BC, Canada), A. Tardon (Oviedo, Spain), C. Chen (Seattle, WA, USA), S.E. Bojesen (Copenhagen, Denmark), M. Johansson (Lyon, France), P. Brennan (Lyon, France), A. Risch (Heidelberg, Germany), H. Bickeboller (Goettingen, Germany), H.-E. Wichmann (Munich, Germany), D. Christiani (Boston, MA, USA), G. Rennert (Haifa, Israel), S. Arnold (Lexington, KY, USA), J.K. Field (Liverpool, UK), S.S. Shete (Houston, TX, USA), L. Le Marchand (Honolulu, HI, USA), O. Melander (Lund, Sweden), H. Brunnström (Lund, Sweden), G. Liu (Toronto, ON, Canada), A. Andrew (Lebanon, NH, USA), L.A. Kiemeny (Nijmegen, the Netherlands), S. Zienoldiny-Narui (Oslo, Norway), K. Grankvist (Umea, Sweden), N. Cporaso (NIH, Bethesda, MD, USA), A. Cox (Sheffield, UK), P. Lazarus (Spokane, WA, USA), M.B. Schabath (Tampa, FL, USA), and M.C. Aldrich (Nashville, TN, USA).

Additional MMAC investigators: D.T. Bishop (Leeds, UK), J.E. Lee (Houston, TX, USA), M. Brossard (Paris, France), N.G. Martin (Brisbane, QLD, Australia), E.K. Moses (Perth, WA, Australia), F. Song (Tianjin, China), J.H. Barrett (Heidelberg, Germany), D.F. Easton (Cambridge, UK), P.D. Pharoah (Cambridge, UK), A.J. Swerdlow (London, UK), K.P. Kypreou (Athens, Greece), J.C. Taylor (Leeds, UK), M. Harland (Leeds, UK), J. Randerson-Moor (Leeds, UK), L.A. Akslen (Bergen, Norway), P.A. Andresen (Oslo, Norway), M.F. Avril (Paris, France), E. Azizi (Tel Aviv, Israel), G.B. Scarrà (Genoa, Italy), K.M. Brown (Bethesda, MD, USA), T. Dębniak (Szczecin, Poland), D.L. Duffy (Brisbane, QLD, Australia), D.E. Elder (Philadelphia, PA, USA), S. Fang (Houston, TX, USA), E. Friedman (Tel Aviv, Israel), P. Galan (Bobigny, France), P. Ghiorzo (Genoa, Italy), E.M. Gillanders (Baltimore, MD, USA), A.M. Goldstein (Bethesda, MD, USA), N.A. Gruis (Leiden, the Netherlands), J. Hansson (Stockholm, Sweden), P. Helsing (Oslo, Norway), M. Hočevár (Ljubljana, Slovenia), V. Höiom (Stockholm, Sweden), C. Ingvar (Lund, Sweden), P.A. Kanetsky (Tampa, FL, USA), W.V. Chen (Houston, TX, USA), GenoMEL Consortium, Essen-Heidelberg Investigators, SDH Study Group, Q-MEGA and QTWIN Investigators, AMFS Investigators, ATHENS Melanoma Study Group, M.T. Landi (Bethesda, MD, USA), J. Lang (Glasgow, UK), G.M. Lathrop (Montreal, QC, Canada), J. Lubiński (Szczecin, Poland), R.M. Mackie (Glasgow, UK), G.J. Mann (Sydney, NSW, Australia), A. Molven (Bergen, Norway), G.W. Montgomery (Brisbane, QLD, Australia), S. Novaković (Ljubljana, Slovenia), H. Olsson (Lund, Sweden), S. Puig (Barcelona, Spain), J.A. Puig-Butlle

(Barcelona, Spain), W. Wu (Indianapolis, IN, USA), A.A. Qureshi (Providence, RI, USA), D.C. Whiteman (Brisbane, QLD, Australia), J.E. Craig (Adelaide, SA, Australia), D. Schadendorf (Essen, Germany), L.A. Simms (Indianapolis, IN, USA), K.P. Burdon (Tasmania, TAS, Australia), D.R. Nyholt (Brisbane, QLD, Australia), K.A. Pooley (Cambridge, UK), N. Orr (London, UK), A.J. Stratigos (Athens, Greece), A.E. Cust (Sydney, NSW, Australia), S.V. Ward (Perth, WA, Australia), N.V. Hayward (Brisbane, QLD, Australia), J. Han (Indianapolis, IN, USA), H.J. Schulze (Münster, Germany), A.M. Dunning (Cambridge, UK), J.A. Bishop (Leeds, UK), F. Dumenais (Paris, France), and S. MacGregor (Brisbane, QLD, Australia).

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

- Zhang X, Guarin D, Mohammadzadehonorvar N, Chen X, Gao X. Parkinson's disease and cancer: a systematic review and meta-analysis of over 17 million participants. *BMJ Open* 2021;11(7):e046329.
- Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson's disease: a meta-analysis. *Arch Gerontol Geriatr* 2015;61(3):510–516.
- Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. *Epidemiology* 2002;13(2):157–164.
- Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. *Cancer Causes Control* 2007;18(7):705–711.
- Cui X, Liew Z, Hansen J, Lee PC, Arah OA, Ritz B. Cancers preceding Parkinson's disease after adjustment for bias in a Danish population-based case-control study. *Neuroepidemiology* 2019;52(3–4):136–143.
- Hayes-Larson E, Shaw C, Ackley SF, et al. The role of dementia diagnostic delay in the inverse cancer-dementia association. *J Gerontol, Ser A* 2022;77(6):1254–1260.
- Ospina-Romero M, Glymour MM, Hayes-Larson E, et al. Association between Alzheimer disease and cancer with evaluation of study biases: a systematic review and meta-analysis. *JAMA Netw Open* 2020;3(11):e2025515–e2025515.
- Mencke P, Hanss Z, Boussaad I, Sugier PE, Elbaz A, Krüger R. Bidirectional relation between Parkinson's disease and glioblastoma multiforme. *Front Neurol* 2020;11:898.
- Filippou PS, Outeiro TF. Cancer and Parkinson's disease: common targets, emerging hopes. *Mov Disord* 2021;36(2):340–346.
- Moriarty N, Moriarty J. Highlighting the link between Parkinson's disease and malignant melanoma: a case report and literature review. *Eur J Case Reports Intern Med* 2019;6(11):1.
- Inzelberg R, Flash S, Friedman E, Azizi E. Cutaneous malignant melanoma and Parkinson disease: common pathways? *Ann Neurol* 2016;80(6):811–820.
- Jiang ZC, Chen XJ, Zhou Q, Gong XH, Chen X, Wu WJ. Down-regulated LRRK2 gene expression inhibits proliferation and migration while promoting the apoptosis of thyroid cancer cells by inhibiting activation of the JNK signaling pathway. *Int J Oncol* 2019;55(1):21–34.
- Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. *J Mol Med* 2014;92(1):31–42.
- Bartek J, Hodny Z. PARK2 orchestrates cyclins to avoid cancer. *Nat Genet* 2014;46(6):527–528.
- Warø BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease. *Brain Behav* 2018;8(1):e00858.
- Inzelberg R, Samuels Y, Azizi E, et al. Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. *Neurol Genet* 2016;2(3):e70.
- Devine MJ, Plun-Favreau H, Wood NW. Parkinson's disease and cancer: two wars, one front. *Nat Rev Cancer* 2011;11(11):812–823.
- Senkevich K, Bandres-Ciga S, Yu E, Liyanage UE, Noyce AJ, Gan-Or Z. No evidence for a causal relationship between cancers and Parkinson's disease. *J Parkinsons Dis* 2021;11(2):801–809.
- Dong J, Gao J, Nalls M, et al. Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. *Neurobiol Aging* 2014;35(6):1512.e5–1512.e10.
- Dube U, Ibanez L, Budde JP, et al. Overlapping genetic architecture between Parkinson disease and melanoma. *Acta Neuropathol* 2020;139(2):347–364.
- Forés-martos J, Boulosa C, Rodrigo-domínguez D, et al. Transcriptomic and genetic associations between alzheimer's disease, parkinson's disease, and cancer. *Cancers* 2021;13(12):2990.
- Domenighetti C, Sugier PE, Sreelatha AAK, et al. Mendelian randomisation study of smoking, alcohol, and coffee drinking in relation to Parkinson's disease. *J Parkinsons Dis* 2022;12(1):267–282.
- Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 2019;18(12):1091–1102.
- Blauwendraat C, Iwaki H, Makarious MB, et al. Investigation of autosomal genetic sex differences in Parkinson's disease. *Ann Neurol* 2021;90(1):35–42.
- Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. *Nature* 2017;551(7678):92–94.
- Law MH, Bishop DT, Lee JE, et al. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. *Nat Genet* 2015;47(9):987–995.
- Schumacher FR, Al Olama AA, Berndt SI, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet* 2018;50(7):928–936.
- McKay JD, Hung RJ, Han Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nat Genet* 2017;49(7):1126–1132.
- Phelan CM, Kuchenbaecker KB, Tyrer JP, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet* 2017;49(5):680–691.
- Truong T, Lesueur F, Sugier PE, et al. Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. *Int J Cancer* 2021;148(12):2935–2946.
- Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet* 2015;47(11):1236–1241.
- Liyanarachchi S, Gudmundsson J, Ferkingstad E, et al. Assessing thyroid cancer risk using polygenic risk scores. *Proc Natl Acad Sci U S A* 2020;117(11):5997–6002.
- Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. *Am J Hum Genet* 2019;104(1):21–34.
- Yang X, Leslie G, Gentry-Maharaj A, et al. Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *J Med Genet* 2018;55(8):546–554.
- König IR, Loley C, Erdmann J, Ziegler A. How to include chromosome X in your genome-wide association study. *Genet Epidemiol* 2014;38(2):97–103.

36. Gu F, Chen TH, Pfeiffer RM, et al. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. *Hum Mol Genet* 2018;27(3):4145–4156.
37. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539–1558.
38. Johnson T. Efficient calculation for multi-SNP genetic risk scores. 2012.
39. Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet* 2017;49(10):1511–1516.
40. Chen C, Zheng H, Hu Z. Association between Parkinson's disease and risk of prostate cancer in different populations: an updated meta-analysis. *Sci Rep* 2017;7(1):1–6.
41. Rashkin SR, Graff RE, Kachuri L, et al. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. *Nat Commun* 2020;11(1):1–14.
42. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. *Lung Cancer* 2001;31(2–3):139–148.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.